Updated Medication Costs From A Real-Life Cost-Effectiveness Evaluation Of Budesonide/Formoterol Maintenance And Reliever Therapy In Asthma Maintenance And Reliever Therapy In Asthma.

per patient and year compared to SEK 4 710.9 in 2006 per patient and year. The budesonide/formoterol MART arm was also less costly compared to the FDC arm (SEK 4 163.2 per patient and year) and to the FAC arm (SEK 7 498.5 per patient and year) (Table 2). Similar results were found in Denmark where medication costs for the budesonide/formoterol MART arm (DuoResp® Spiromax®) were less in 2015 DKK 4 183.5 compared to DKK 4 573 in 2006. The budesonide/formoterol MART arm was also less costly than the FAC arm (DKK 4 510.4) as well as the FDC arm (DKK 4 579) per patient and year (Table 3). The cost savings for using Duoresp® Spiromax ® instead of Symbicort® Turbohaler® in Sweden and Denmark are further highlighted in Figure 1 for the 160/4.5 mg dosing strategy and in Figure 2 for the 320/9 mg dosing strategy. Direct health care utilisation and drug usage was sourced from the real-life cost-effectiveness analysis from 2008 and applied in the updated analyses for Sweden and Denmark (Table 1). Health care utilisation unit costs and medication costs from 2006 were inflated to 2015 price levels and then compared to today’s actual prices of medications used in the budesonide/formoterol MART arm (DuoResp® Spiromax®), the FDC arm (Bufomix® Easyhaler® plus terbutaline as needed) , and the FAC arm (Pulmicort® Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed). The prices were sourced from the TLV (4) and from Lagemiddelstyrelsen (5) in June 2015. UPDATED MEDICATION COSTS FROM A REAL-LIFE COST-EFFECTIVENESS EVALUATION OF BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY IN ASTHMA Medin E1, Safioti G2, Lindqvist F2, Torvinen S3